- Home
- UHAL vs ARWR Comparison
UHAL vs ARWR Comparison
Compare UHAL & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UHAL | ARWR |
|---|---|---|
| Founded | 1945 | 2003 |
| Country | United States | United States |
| Employees | 35100 | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.3B |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | UHAL | ARWR |
|---|---|---|
| Price | $50.69 | $78.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $83.40 |
| AVG Volume (30 Days) | 169.8K | ★ 1.6M |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,142,321.00 |
| Revenue This Year | $5.89 | N/A |
| Revenue Next Year | $4.41 | N/A |
| P/E Ratio | $78.63 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $41.95 | $14.30 |
| 52 Week High | $66.30 | $80.27 |
Technical Indicators
Market Signals| Indicator | UHAL | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 63.76 |
| Support Level | $50.28 | $60.60 |
| Resistance Level | $52.25 | N/A |
| Average True Range (ATR) | 1.11 | 3.66 |
| MACD | -0.28 | 0.18 |
| Stochastic Oscillator | 15.43 | 93.65 |
Price Performance
Historical ComparisonAbout UHAL U-Haul Holding Company
U-Haul Holding Co is an American moving truck, trailer, and self-storage rental company. The company also provides moving boxes, packing supplies, LPG (propane) refills, trailer hitch and wiring installation, storage container rentals, and other services. It has three reportable segments Moving and Storage, Property and Casualty Insurance, and Life Insurance. The majority of its revenue comes from the Moving and Storage segment.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.